Vital Ksk Holdings Inc

Vital Ksk Holdings Inc maintains a strong liquidity position, with a current ratio of 1.07 and cash and equivalents amounting to ¥23,099,000,000. The company's liquidity FPT (free cash flow to total liabilities) is supported by a free cash flow of ¥4,669,000,000 and total liabilities of ¥193,513,000,000. Profitability metrics indicate a moderate return on equity of 6.9% and a return on assets of 2.44%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals & Medical Research sector, suggesting room for improvement in asset utilization and capital efficiency. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. Growth trajectory is modest, with no significant revenue growth reported in the latest period. The company's operating cash flow is negative at ¥8,023,000,000, indicating potential challenges in sustaining operations from core business activities. Risk assessment reveals low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.08 suggests a conservative capital structure, with long-term debt at ¥8,540,000,000 and total equity at ¥105,913,000,000. Recent financial filings and transcripts do not indicate any material events or strategic shifts. The company's capital expenditure of ¥4,337,000,000 reflects ongoing investment in infrastructure and operations.